Petrovic Lydia M
Department of Pathology, New York University School of Medicine, NY, USA.
Liver Int. 2007 Jun;27(5):598-606. doi: 10.1111/j.1478-3231.2007.01478.x.
Human immunodeficiency virus/hepatitis C virus (HIV/HCV) co-infection has emerged as a leading cause of liver morbidity in the last two decades. Liver failure is also frequently a cause of death in HIV/HCV co-infected patients. Highly active antiretroviral treatment (HAART) has revolutionized the HIV treatment, leading to a significantly decreased morbidity, prolonged survival, and an overall better outcome of HIV infection. Hepatotoxicity associated with antiretroviral treatment, however, has been recognized as one of the serious complications of the treatment. The effects of HIV infection on the natural history and progression of HCV-associated chronic liver disease that had been well documented in the pre-HAART treatment era have been changing, and there are now many indications that HIV/HCV co-infection should be recognized as an evolving and a challenging disease entity.
在过去二十年中，人类免疫缺陷病毒/丙型肝炎病毒（HIV/HCV）合并感染已成为肝脏疾病的主要病因。肝衰竭也是HIV/HCV合并感染患者常见的死亡原因。高效抗逆转录病毒治疗（HAART）彻底改变了HIV的治疗方式，显著降低了发病率，延长了生存期，并使HIV感染的总体预后得到改善。然而，抗逆转录病毒治疗相关的肝毒性已被认为是该治疗的严重并发症之一。在HAART治疗前的时代，HIV感染对HCV相关慢性肝病自然史和进展的影响已有充分记录，而现在有许多迹象表明，HIV/HCV合并感染应被视为一种不断演变且具有挑战性的疾病实体。
